Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adenovirus Infection Clear all
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jun 10, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

NCT02143804
View directory record Official record
Conditions
Bladder Cancer, High Grade, Non Muscle Invasive
Interventions
oncolytic adenovirus expressing GMCSF
Biological
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 10, 2026, 1:48 AM EDT
Recruiting Phase 1 Interventional

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

NCT05686798
View directory record Official record
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme, GBM
Interventions
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

NCT02197169
View directory record Official record
Conditions
Glioblastoma or Gliosarcoma
Interventions
Single intratumoral injection of DNX-2401, Interferon-gamma
Drug
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

NCT02087306
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jun 10, 2026, 1:48 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

NCT00695877
View directory record Official record
Conditions
HIV Infections
Interventions
Ad5.ENVA.48 HIV-1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

NCT04591717
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD vaccine
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

NCT00583024
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
ADENOVIRUS/PSA VACCINE
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

NCT00964756
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Ad5.SSTR/TK.RGD, Ganciclovir (GCV)
Genetic · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Jun 10, 2026, 1:48 AM EDT
Terminated No phase listed Observational

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

NCT02420080
View directory record Official record
Conditions
Adenovirus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Washinton, District of Columbia • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

NCT00270218
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients

NCT00270465
View directory record Official record
Conditions
HIV
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer

NCT01972737
View directory record Official record
Conditions
Colon Cancer
Interventions
Ad5-hGCC-PADRE vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Jun 10, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

Third Party Viral Specific T-cells (VSTs)

NCT02532452
View directory record Official record
Conditions
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Interventions
Viral Specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Days and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
4
States / cities
Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1Phase 2 Interventional

Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)

NCT04125732
View directory record Official record
Conditions
Coronary Artery Disease, Ischemia, Angina Refractory, Cardiovascular Diseases, Heart Diseases
Interventions
AdVEGFXC1
Biological
Lead sponsor
XyloCor Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Stanford, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Experimental AD4-H5-VTN Vaccine in Healthy Volunteers

NCT01443936
View directory record Official record
Conditions
H5N1 Influenza
Interventions
Ad4-H5-VTN vaccination-tonsillar route, Ad4-H5-vaccination-oral route
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

NCT00394693
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Adenovirus Interferon gamma
Genetic
Lead sponsor
Transgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Jun 10, 2026, 1:48 AM EDT
Recruiting Phase 1 Interventional

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

NCT03896568
View directory record Official record
Conditions
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
Interventions
Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery
Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 1:48 AM EDT
Recruiting Phase 1 Interventional

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

NCT03425526
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Interventions
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 10, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer

NCT03281382
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Ad5-yCD/mutTKSR39rep-hIL12
Biological
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 10, 2026, 1:48 AM EDT